PRGTX
Price
$38.28
Change
+$0.51 (+1.35%)
Updated
Jun 2 closing price
Net Assets
8.57B
WFSTX
Price
$11.00
Change
+$0.05 (+0.46%)
Updated
Jun 2 closing price
Net Assets
366.44M
Interact to see
Advertisement

PRGTX vs WFSTX

Header iconPRGTX vs WFSTX Comparison
Open Charts PRGTX vs WFSTXBanner chart's image
PRGTX vs WFSTX Comparison Chart in %
View a ticker or compare two or three
VS
PRGTX vs. WFSTX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRGTX is a Buy and WFSTX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PRGTX has more cash in the bank: 8.57B vs. WFSTX (366M). PRGTX (0.00) and WFSTX (0.00) have matching dividends . PRGTX was incepted earlier than WFSTX: PRGTX (26 years) vs WFSTX (26 years). WFSTX (1.30) is less costly to investors than PRGTX (0.93). WFSTX (35.00) and PRGTX (34.60) have comparable annual turnover. WFSTX has a lower initial minimum investment than PRGTX: WFSTX (1000) vs PRGTX (2500). PRGTX annual gain was more profitable for investors over the last year : 79.69 vs. WFSTX (-9.50). PRGTX return over 5 years is better than : 33.94 vs. WFSTX (-41.69).
PRGTXWFSTXPRGTX / WFSTX
Total Expense Ratio0.931.2276%
Annual Report Gross Expense Ratio0.931.3072%
Fund Existence26 years26 years-
Gain YTD42.2607.458567%
Front LoadN/A6%-
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets8.57B366M2,343%
Annual Yield % from dividends0.000.00-
Returns for 1 year79.69-9.50-838%
Returns for 3 years171.1414.781,158%
Returns for 5 years33.94-41.69-81%
Returns for 10 years172.3114.541,185%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FRMM4.780.21
+4.60%
Forum Markets Incorporated
ACTG4.720.09
+1.94%
Acacia Research Corp
CNA42.240.34
+0.81%
CNA Financial Corp
CHSCO26.23-0.01
-0.04%
CHS
BCRX8.35-0.23
-2.63%
BioCryst Pharmaceuticals